Indian court lifts stay on Cipla's generic Sutent; firm slashes prices of anticancers
This article was originally published in Scrip
The Supreme Court of India has lifted a lower court stay against Cipla in a case concerning the potential launch of its cut-price generic version of Pfizer's anticancer, Sutent (sunitinib malate). The court action came on a day that also saw Cipla announce massive price cuts for three of its other generic anticancers.
You may also be interested in...
New rules in India specify that a marketer of a drug will share the onus for quality and compliance along with the manufacturer. Enhanced punishment for misleading advertisements for a range of illnesses is also proposed, while calls for a statute to regulate pharma's marketing practices grow louder.
Former managing director of Janssen India to helm Bharat Serums and Vaccines following the firm’s acquisition by private equity firm Advent International.
Deal news from Strides Pharma, Pharmaceutics Intl., Cipla, Wanbury, AstraZeneca, Syntekabio, Arctoris, Mundipharma, Samsung Bioepis…